Home/ReGenX Biosciences/Kenneth T. Mills
KT

Kenneth T. Mills

President and Chief Executive Officer

ReGenX Biosciences

Roles

President and Chief Executive OfficeratReGenX Biosciences
President and Chief Executive OfficeratREGENXBIO

ReGenX Biosciences Pipeline

DrugIndicationPhase
RGX-314Wet Age-Related Macular Degeneration (wAMD)Phase II
RGX-121Mucopolysaccharidosis Type II (MPS II)Phase I/II
RGX-181CLN2 Disease (Batten Disease)Phase I/II
RGX-111Mucopolysaccharidosis Type I (MPS I)Phase I/II
RGX-381Ocular manifestations of Epidermolysis BullosaPhase I/II